Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Clinical trial NCT05877430 · RECRUITING
Trial details
- NCT number
- NCT05877430
- Sponsor
- CJ Bioscience, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-11
- Primary completion
- 2026-07-01
- Enrollment
- 160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.